title: The hemostatic role of factor XI.
abstract: Coagulation factor (F)XI has been described as a component of the early phase of the contact pathway of blood coagulation, acting downstream of factor XII. However, patients deficient in upstream members of the contact pathway, including FXII and prekallikrein, do not exhibit bleeding complications, while FXI-deficient patients sometimes experience mild bleeding, suggesting FXI plays a role in hemostasis independent of the contact pathway. Further complicating the picture, bleeding risk in FXI-deficient patients is difficult to predict because bleeding symptoms have not been found to correlate with FXI antigen levels or activity. However, recent studies have emerged to expand our understanding of FXI, demonstrating that activated FXI is able to activate coagulation factors FX, FV, and FVIII, and inhibit the anti-coagulant tissue factor pathway inhibitor (TFPI). Understanding these activities of FXI may help to better diagnose which FXI-deficient patients are at risk for bleeding. In contrast to its mild hemostatic activities, FXI is known to play a significant role in thrombosis, as it is a demonstrated independent risk factor for deep vein thrombosis, ischemic stroke, and myocardial infarction. Recent translational approaches have begun testing FXI as an antithrombotic, with one promising clinical study showing that an anti-sense oligonucleotide against FXI prevented venous thrombosis in elective knee surgery. A better understanding of the varied and complex role of FXI in both thrombosis and hemostasis will help to allow better prediction of bleeding risk in FXI-deficient patients and also informing the development of targeted agents to inhibit the thrombotic activities of FXI while preserving hemostasis.
authors.affiliation: Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, United States; Division of Hematology and Medical Oncology, School of Medicine, Oregon Health & Science University, Portland, OR, United States. Electronic address: puygarci@ohsu.edu.
authors.forename: Cristina
authors.initials: C
authors.lastname: Puy
authors.affiliation: Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, United States.
authors.forename: Rachel A
authors.initials: RA
authors.lastname: Rigg
authors.affiliation: Department of Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, United States; Division of Hematology and Medical Oncology, School of Medicine, Oregon Health & Science University, Portland, OR, United States.
authors.forename: Owen J T
authors.initials: OJ
authors.lastname: McCarty
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000494:pharmacology / Q000627:therapeutic use; D001777:Blood Coagulation / Q000187:drug effects; D055808:Drug Discovery; D005172:Factor XI / Q000378:metabolism*; D005173:Factor XI Deficiency / Q000097:blood / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D006470:Hemorrhage / Q000097:blood / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*
chemical_list: D000925:Anticoagulants; D005172:Factor XI
keywords: bleeding; coagulation factor XI; coagulation factor XII; contact activation pathway; hemophilia C; hemostasis